2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 DiabetesGuruFocus · 4 days ago
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 DiabetesBusiness Wire · 4 days ago
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?Zacks Investment Research · 5 days ago
Corcept Therapeutics (NASDAQ:CORT) Director Sells $1,148,100.00 in StockDefense World · 5 days ago
Corcept Therapeutics Incorporated $CORT Stock Holdings Cut by First Citizens Bank & Trust Co.Defense World · 6 days ago
Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 GainsZacks Investment Research · Oct 16, 2026Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 29, 2026 | $0.02 | $0.36 | Beat |
| Apr 30, 2026 | -$0.11 | -$0.30 | Miss |
| Feb 24, 2026 | $0.33 | $0.20 | Miss |
| Nov 4, 2025 | $0.18 | $0.16 | Miss |
| Jul 31, 2025 | $0.23 | $0.29 | Beat |
| May 5, 2025 | $0.17 | $0.17 | Beat |